news grtaphic
Pain Product News and Warnings
radio graphic

We CRPS sufferers use many drugs and other products approved for the treatment of pain, muscle spasms, depression, anxiety, insomnia, and the multitude of other ways in which we feel lousy so much of the time. Since our pharmacopœia is so large and diverse, it's important to stay abreast of any news about these medications, and especially any warnings of unexpected (particularly dangerous or harmful) effects of a drug, which should be disseminated as fast as possible.

Material for this page is drawn from a variety of sources, including the FDA, the excellent Pain-Topics web site, and other abstracting services available for such alerts. Specific sites you may find instructive are, the FDA page on recalls,,, and the Institute For Safe Medication Practices.

To aid in scanning the links for news specific to your personal medication situation, drug names are presented in white and one font bigger than the surrounding text. I hope it proves useful.

NOTE: The great majority of these alerts are summaries published periodically by the excellent highlighting service Pain-Topics ( Their publication schedule appears to be whenever they feel that it important to get the contained information out to the public. You can see from the top five entries that the spacing varies widely. Please be assured that I will post these important updates within days of their appearance on the Internet. (I note this because a visitor asked why they didn't appear every month.)

Note: All links open in a new tab/window
Pain Med News/Warnings - Most Recent Listed First
Site (& link)
blinking bulbNovember 2013 – Pain Product Announcements & Warnings
Featured Items: hydrocodone (Zohydro ER) approved as a single-entity product; FDA announces plan for hydrocodone combination products reclassification; diclofenac capsules (Zorvolex) approved as new NSAID formulation; tocilizumab (Actemra) subcutaneous formulation approved for RA; certolizumab pegol (Cimzia) approved for active psoriatic arthritis; methotrexate (Otrexup) self-injection device approval;. — All brand names are trademarks of their respective manufacturers.
October 2013 – Pain Product Announcements & Warnings
"Featured Items: Ustekinumab (Stelara) approved for active psoriatic arthritis; fentanyl pain patch color change; new safety measures for ER/LA opioid analgesics; new 15-mcg/hour dose for buprenorphine patch (Butrans); fluoroquinolone warning of peripheral neuropathy risk; MOTRIN drops product recall; Ortiga safety warning regarding hidden drug ingredient; new warnings for Arzerra and Rituxan; bupivacaine single-dose vial recall.
August 2013 – Pain Product Announcements & Warnings
"Featured Items: Golimumab infusion (Simponi ARIA) approved for rheumatoid arthritis; acetaminophen warning of serious skin reactions; Medtronic pain pump recalls."
May 2013 – Pain Product Announcements & Warnings
"Featured Items: lubiprostone (Amitiza) approved for treating opioid-induced constipation; controlled-release oxycodone HCl (OxyContin) abuse-deterrent labeling approved; generic versions of Suboxone (buprenorphine/naloxone) receive FDA approvals."
February 2013 – Pain Product Announcements & Warnings
"Featured Items: sumatriptan iontophoretic patch (Zecuity) approved for migraine; 2 new crush-resistant strengths for oxymorphone (Opana ER); FDA warning that Rheumofan-Plus is renamed and relabeled; recall for hydrocodone-acetaminophen tablets.
December 2012 – Pain Product Announcements & Warnings
"Featured Items: tofacitinib citrate (Xeljanz) approved for RA; tocilizumab (Actemra) expanded approval for RA; linaclotide (Constella) approved in Europe for IBS; adalimumab (Humira) approved for pediatric Crohn's disease; lidocaine/tetracaine cream (Pliaglis) FDA approved; SENSUS pain management system FDA cleared."
October 2012 – Pain Product Announcements & Warnings
"Featured Items: adalimumab (Humira) approved for ulcerative colitis; buprenorphine/naloxone tablet (Suboxone) production halted; topical OTC analgesics product safety alert; 2 lots of hydrocodone-acetaminophen combination tablets recalled."
September 2012 – Pain Product Announcements & Warnings
"Featured Items: tapentadol extended-release (Nucynta ER) approved for diabetic peripheral neuropathy; linaclotide (Linzess) capsules approved for IBS-C and Chronic Idiopathic Constipation; extended-release hydromorphone hcl (Exalgo) 32-mg strength approved; Reumofan Plus recall and updated safety warning; prefilled Carpuject hydromorphone syringe single lot recall."
August 2012 – Pain Product Announcements & Warnings
"Featured Items: delayed-release prednisone (Rayos) approved for rheumatoid arthritis and 5 additional indications; generic pregabalin approved; FDA REMS approval for long-acting and extended-release opioids; makers of unapproved oxycodone products warned to stop; defective Hospira injectable vials recalled."
July 2012 – Pain Product Announcements & Warnings
Featured Items: pregabalin (Lyrica) approved for neuropathic pain in spinal cord injury; gabapentin enacarbil (Horizant) approved for postherpetic neuralgia; OPANA ER conversion to crush-resistant tablets; supplement Reumofan-Plus recalled for undeclared drugs."
May 2012 – Pain Product Announcements & Warnings
"Featured Items: rotigotine transdermal system (Neupro) approved for RLS; adalimumab (Humira) European approval for colitis; fentanyl patch safety alert; proton pump inhibitor (PPI) alert for C. difficile-associated diarrhea; Savella and Neurontin added to FDA Watch list; morphine sulfate injectable recall."
Feb. 2012 – Pain Product Announcements & Warnings
"Featured Items: Fentanyl sublingual spray (Subsys®) approved for breakthrough cancer pain; FDA safety alert regarding Endo/Novartis opioid product packaging problem; natalizumab (Tysabri®) FDA safety alert; FDA approval of TIRF REMS program."
Jan 2012 – Pain Product Announcements & Warnings
"Featured Items: extended-release oxymorphone (Opana ER) FDA approved in crush-resistant formulation; first-time generic FDA approval of morphine sulfate ER (Kadian equivalent)."
Dec 2011 – Pain Product Announcements & Warnings
"Featured Items: bupivacaine liposome injectable suspension (Exparel) approved for postsurgical pain; onabotulinumtoxinA (BOTOX) approved for chronic migraine prophylaxis; TNF Blockers, azathioprine, and/or mercaptopurine - FDA safety update; duloxetine (Cymbalta) approval denied in Europe for chronic musculoskeletal pain."
Oct 2011 – Pain Product Announcements & Warnings
"Featured Items: infliximab (Remicade) approved for pediatric ulcerative colitis; tumor necrosis factor-alpha (TNFa) blocker safety warning; ondansetron (Zofran) safety warning."
Uprizing 2.0, a testosterone booster, was recalled 10/3/11 due to contamination with superdrol, an unapproved steroid.
"Tapentadol extended-release tablets (Nucynta) approved for chronic pain; subcutaneous abatacept (Orencia) approved for rheumatoid arthritis; citalopram hydrobromide (Celexa) safety warning."
"FDA notified healthcare professionals and patients of an update to the drug label for Reclast (zoledronic acid) regarding the risk of kidney failure. Cases of acute renal failure requiring dialysis or having a fatal outcome following Reclast use have been reported to FDA."
"Fentanyl nasal spray (Lazanda) approved for cancer pain; mesalamine (Lialda) approved for ulcerative colitis remission maintenance; acetaminophen (Extra Strength Tylenol) maximum daily dosing change & recall; Actiq and Fentora REMS released."

purple line